Combination Rota–Polio vaccine formulations for oral administration, stable at -200 C for atleast 12 months or more in both liquid and lyophilized form, comprising human-bovine natural ressortants and naturally attenuated Rotavirus strains selected from Rotavirus 116E, Rotavirus I321 and tetravalent UK Bovine Human ...

The present invention relates to a pharmaceutical formulation capable of eliciting protective immune response against Chikungunya virus infection in humans and other mammalian hosts. The immunogenic formulation comprises purified inactivated Chikungunya virus in a stable formulation. Methods of propagation and purif...

The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods o...

The invention relates to combined heptavalent liquid vaccine with a single injection to provide better immunity in children. The heptavalent vaccine of the invention comprises combination heptavalent (IPV-IRV-Hib-HBsAg-DPT) vaccine for multiple immunogenicity in human beings, comprising Inactivated poliovirus (Sabin...

Novel muramyl dipeptide derivative compound represented by the structural Formula-VIII (MDP-AA) and a process for synthesis thereof are disclosed. Structural Formula-VIII (MDP-AA) Wherein, ‘n’ can be any natural number(s), and: wherein R or R1 is selected from the group consisting of a hydrogen, heteroatom sub...

VACCINE COMPOSITIONS The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis vir...

A vaccine composition for prophylaxis and treatment of Chikungunya virus infections is disclosed which is capable of conferring immunity against any genotypic variants of the Chikungunya virus. More particularly the invention discloses particular nucleotide sequences and their translated proteins thereof, which may ...

The invention provides novel processes and appropriate experimental techniques which would maximize antigen yield, and also stabilize Vero-cell derived purified inactivated Japanese encephalitis virus bulk. Alternative methods of cell culture and virus culture are disclosed for commercial manufacture of vaccine form...

The present invention is related to pharmaceutical formulations capable of eliciting protective immune response against Chandipura virus infection in humans and other mammalian hosts. The immunogenic formulation comprises Chandipura virus glycoprotein (G protein) and/or nucleoprotein expressed as recombinant protein...

The invention describes a stable immunogenic protein having multiple cysteines molecules wherein the protein is having stability up to two years and purity more than 98% particularly rPvRII and/or rPfF2. It also discloses a method for producing said immunogenic protein comprising the following steps: culturing the h...

Compositions and methods related to live or live attenuated pre-conditioned and typical viruses such as rotaviruses are disclosed. The live attenuated rotaviruses exhibit better stability characteristics and are useful for the prevention of a rotavirus infection and/or rotavirus gastroenteritis in children. ...

NA

A novel synergistic pharmaceutical composition for preparation of topical formulations for prophylaxis and treatment of wounds, burn wounds, skin grafts, pressure ulcers and diabetic foot ulcers is disclosed. The synergistic composition comprises a mitogenic protein in combination with one or more bactericidal an...

ABSTRACT VACCINE COMBINATIONS Vaccine combinations which comprise atleast two or more of the following antigens: DTap-HEV-HepB-HPV suitable for administration in humans. A number of variations in the combination of these antigens have been disclosed that is suitable for concomitant administration. The methods of p...

Vaccine compositions and processes for culturing the pathogenic bacteria containing virulent polysaccharides in animal free culture medium  isolation  purification of polysaccharides and polysaccharide-protein conjugate without employing alcohol for preparing immunogenic formulations. The immunogens obtained from th...

A BUFFER FREE, ACID STABLE LOW DOSE VOLUME ROTAVIRUS VACCINE A buffer free, acid stable, low dose volume rotavirus vaccine is disclosed. The vaccine is available in dose volume of less than 1 ml per dose for oral administration and it is without any buffer. The vaccine also does not require pre or post administrat...

ABSTRACT NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF The invention relates to novel Muramyl Dipeptide (MDP) derivative compound of structural Formula-VIII, a process for synthesis, intermediates used in the synthesis and use thereof. Wherein, R can be both linear and branched alkyl, ary...

ABSTRACT NOVEL MURAMYL PEPTIDE DERIVATIVE COMPOUND, SYNTHESIS AND USES THEREOF The invention relates to novel Muramyl Dipeptide (MDP) derivative compound of structural Formula-VIII, a process for synthesis, intermediates used in the synthesis and use thereof; wherein Ri and R^both are hydrogen; or Ri is hydrogen...

The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods o...

Invention provides novel rotavirus vaccine compositions comprising rotavirus antigens, stabilizers and buffers. The buffers in the invention are pre-mixed in the rotavirus vaccine compositions to neutralize the high acidic pH of the stomach without requiring separate administration of an antacid before vaccine admin...

Conserved epitopes selected from EV71 and CVA16, the two major causative agents of Hand Foot and Mouth Disease has been used to develop sub-unit bivalent vaccine antigen construct. The said vaccine described in this invention is capable to provide cross-protection to diverse EV71 and CVA16 infection causing strains....

ADJUVANTS The invention discloses novel adjuvant formulations comprising Cholecalciferol as vaccine adjuvant in a suitable formulations. The said formulation includes Cholecalciferol, an oil base, a lipid base, a fat soluble hydrophobic solvent, a surfactant or an emulsifier, in any pharmaceutically acceptable bu...

The present invention pertains to the field of industrial scale inactivation of various enteroviruses and large and industrial scale production of enterovirus vaccine compositions and combinations of various enteroviruses so obtained.

Disclosed are multivalent conjugate compositions against Salmonella diseases. A combined vaccine composition of glycol-conjugates in tetravalent, trivalent and bivalent combinations are disclosed in the present invention.

The present invention relates to vaccine composition comprising inactivated rotavirus antigen, methods of inactivation and preparation of vaccine composition thereof. The present invention also discloses a combination vaccine comprising inactivated rotavirus antigen and norovirus antigen, and vaccine preparations th...

The invention generally discloses coronavirus vaccine for coronavirus disease. Particularly, the invention discloses coronavirus vaccine through nasal immunization. More particularly, the invention describes and develop a preventive vaccine against infection or disease caused by severe acute respiratory syndrome cor...

The present invention relates to vaccine and treatment of novel coronavirus (SARS-CoV-2) infection (COVID-19) in mammals. Particularly, the invention relates to coronavirus vaccine and method for preparation thereof. More particularly, the present invention discloses preparation of coronavirus vaccine comprising an ...

Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S.typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The m...

Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S.typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The m...

The present invention relates to the field of combined vaccine compositions which are effective against all forms of meningococcal diseases as well as typhoid fever. The vaccine formulations comprising antigens from capsular polysaccharides of Neisseria meningitidis A Neisseria meningitidis C Neisseria meningitidis ...

ABSTRACT A CHIMERIC THERAPEUTIC VACCINE Disclosed are recombinant chimeric proteins of human epidermal growth factor that has ability to show both adjuvant activity and anti-tumorigenic property. The present invention discloses the use of recombinant chimeric protein as a therapeutic vaccine composition either...

The present invention discloses Enterovirus D68 adapted to propagate to high titers in Vero cells and method of adaptation thereof. The present invention also discloses suitable vaccine composition comprising inactivated Enterovirus D68 antigen.

The invention discloses stable formulations of low abundance enteroviruses vaccines, process of manufacture thereof; and method of isolating the enteroviruses from the clinical sample by propagating in mammalian cell substrate. Low abundance enterovirus from clinical source was isolated by invitro passaging, formula...

The invention relates to novel agonist vaccine formulation, wherein the agonist is novel TLR7/8 agonist which is used as an adjuvant or an immunomodulator. More particularly, the invention relates to the preparation of vaccine formulations against viral infections using Algel-IMDG as an adjuvant. The invention also ...

The invention discloses an adjuvanted inactivated recombinant rabies virus vectored coronavirus vaccine formulation comprising SEPIVAC SWE or MemVax as adjuvant/s. The invention provides vaccine compositions, formulation 1 comprising combination of inactivated recombinant rabies virus vectored antigen and SEPIVAC SW...

The invention discloses vaccine for coronavirus and influenza virus and method for preparation thereof. More specifically, the invention discloses seasonal viral vaccine i. e. coronavirus and influenza virus vaccine for prophylaxis of novel coronavirus (SARS-CoV-2) infection (COVID-19) and Influenza virus in mammals...

The present invention discloses a system and method of generating robust immune response in mammals against SARS-CoV-2 antigen by administering two or more doses of same or different COVID-19 vaccines through same or different routes, wherein at least one vaccine is selected from a primary series of vaccines and at ...

The present invention discloses a cationic lipid-based formulation for in vivo delivery of nucleic acid. The present invention describes the development of a lipid system that can induce efficient non-viral delivery of nucleic acid, especially RNA, for the purpose of efficient nucleic acid transfection toward elicit...

The present invention provides novel self-assembled formulations of lipid nanoparticles (LNPs) comprising cationic lipids: DC-targeting lipids that contain both transfection-enhancing guanidine functionality and DC-targeting mannose-mimicking shikimoyl- functionality in their polar head-group region, endosome-disrup...